Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies

RAF kinase inhibitors are clinically active in patients with BRAF (V600E) mutant melanoma. However, rarely do tumors regress completely, with the majority of responses being short-lived. This is partially mediated through the loss of negative feedback loops after MAPK inhibition and reactivation of...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Exp Med
Glavni autori: Saei, Azad, Palafox, Marta, Benoukraf, Touati, Kumari, Nishi, Jaynes, Patrick William, Iyengar, Prasanna Vasudevan, Muñoz-Couselo, Eva, Nuciforo, Paolo, Cortés, Javier, Nötzel, Christopher, Kumarakulasinghe, Nesaretnam Barr, Richard, John Lalith Charles, Bin Adam Isa, Zul Fazreen, Pang, Brendan, Guzman, Marta, Siqin, Zhou, Yang, Henry, Tam, Wai Leong, Serra, Violeta, Eichhorn, Pieter Johan Adam
Format: Artigo
Jezik:Inglês
Izdano: Rockefeller University Press 2018
Teme:
Research Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6028519/
https://ncbi.nlm.nih.gov/pubmed/29880484
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1084/jem.20171960
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items